Figure 8.

The combination of imatinib and allopurinol reduces the levels of phospho-BCR-ABL, BCR-ABL, and phospho-STAT5. K562 cells were treated with 0.2 μM imatinib, 0.4 mM allopurinol, or their combination for 6 h. The level of the phosphorylated-activated forms of BCR-ABL and STAT5 was analyzed by immunoblotting. The same membranes were stripped and reprobed to detect the total levels of these proteins. GAPDH was used as a loading control. Representative experiments are shown. (a) pBCR-ABL/BCR-ABL levels (n = 6). (b) pSTAT5/STAT5 (n = 4) levels.